MiMedx Group (NASDAQ:MDXG) Stock Rating Lowered by Wall Street Zen

MiMedx Group (NASDAQ:MDXG) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other analysts have also commented on MDXG. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 18th. Craig Hallum lowered their price objective on MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Citizens Jmp cut their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

MiMedx Group Stock Performance

Shares of MDXG opened at $4.13 on Friday. The company has a current ratio of 5.33, a quick ratio of 4.79 and a debt-to-equity ratio of 0.07. MiMedx Group has a 12-month low of $3.03 and a 12-month high of $7.99. The firm has a 50-day moving average price of $3.92 and a 200 day moving average price of $4.23. The firm has a market capitalization of $601.99 million, a P/E ratio of 103.28 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $64.36 million during the quarter, compared to analysts’ expectations of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. Sell-side analysts forecast that MiMedx Group will post -0.09 EPS for the current year.

Hedge Funds Weigh In On MiMedx Group

Several large investors have recently made changes to their positions in the stock. Williams & Novak LLC acquired a new stake in MiMedx Group in the 2nd quarter valued at approximately $53,000. Bank of America Corp DE boosted its position in shares of MiMedx Group by 18.3% during the first quarter. Bank of America Corp DE now owns 572,295 shares of the company’s stock worth $2,261,000 after buying an additional 88,627 shares during the period. Sunbelt Securities Inc. acquired a new stake in shares of MiMedx Group in the first quarter valued at $42,000. Punch & Associates Investment Management Inc. raised its holdings in shares of MiMedx Group by 0.6% in the 1st quarter. Punch & Associates Investment Management Inc. now owns 2,019,718 shares of the company’s stock valued at $7,978,000 after buying an additional 12,524 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of MiMedx Group by 22.4% in the 1st quarter. Renaissance Technologies LLC now owns 3,019,871 shares of the company’s stock valued at $11,928,000 after buying an additional 552,806 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.